Clinical Trial Update: Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial assessed algorithm-based hydroxyurea dosing for sickle cell disease, focusing on fetal hemoglobin response, acute complications, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Sickle Cell Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-08-06